Company News
Special Promotion on Full-length Popular Drug Target Proteins!
a special price of $480 for a 50 μg size or $640 for a 100 μg size
Revolutionizing Drug Development: Synthetic Nanodiscs
Unlock the Potential of ‘Undruggable’ Membrane Proteins
Cancer Research & Immuno-Oncology Week Virtual Event Series 2023
Activity time: October 3 – 5, 2023
DIMA invites you to attend the Cancer Research & Immuno-Oncology Week Virtual Event Series, an online-only virtual event occurring on October 3 – 5, 2023.
Summer Promotion-Popular drug target proteins with 50% OFF
Activity time: 2023.07.01-2023.09.01
In order to appreciate customers’ attention on DIMABIO, we offer 50% OFF on selective Extracellular Domain (ECD) protein products.
PEGS Boston: The Essential Protein Engineering & Cell Therapy Summit 2023
Dates: May 15th -19th, 2023
Location: Boston, MA – Hynes Convention Center and virtual
Using Single B Technology to Develop Lead Antibody Molecules on GPCR Targets with Live Q&A
2023-02-09
We’re presenting at the Drug Discovery ……
Will SIRPα antibody combinatorial therapy be the next research hotspot?
2020-09-02
SIRPα, a transmembrane protein expressed on macrophages and bone marrow cells, binds to its ligand CD47 to produce a “don’t eat me” signal that prevents macrophages from phagocytizing healthy cells.
Immune checkpoints proteins
2020-07-29
Immune checkpoints are regulators that can inhibit or activate our immune system. They play essential roles in maintaining immune tolerance and modulating the duration and strength of immune responses.
New product release: SARS-CoV-2 functional proteins
2020-07-15
To help our customers quickly evaluta the bioactivity of our SARS-CoV-2 S protein products, we include two small packages of CB6 and CR3022 monoclonal antibodies as free sample kit if you order the standard 100 ug or above package.
Events of 2020
2020-04-26
Dima Biotech is attending or presents new products in the following international conferences:
First full length rabbit sourced mAb approved by FDA
2020-03-14
FDA approved the listing of Eptinezumab, a CGRP antibody of Danish Lundbeck pharmaceutical, under the trade name of Vyepti, to prevent migraine On February 22, 2022. Since 1986, FDA has approved more than 90 new monoclonal antibody…